On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two stocks is more ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

The National Medical Products Administration (NMPA) has cleared the drug for triple-negative breast cancer (TNBC), making it ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

A cancer treatment similar to sac-TMT approved for marketing in China is Trodelvy (sacituzumab govitecan-hziy), developed by ...